Hologic (HOLX), a significant player in the bio-tech industry, has been in the lime light for various reasons. It has been approved for listing withdrawal by NASDAQ after previously notifying of such an intent. The company's long-term returns contrast with its current flat stock performance, but it recently recorded a 1.7% YoY revenue gain, despite Q1 2026 Earnings Per Share (EPS) missing consensus estimates. Elevation of conversations is notable, especially amid the company's CEO's Exit and the nearing final closure of a substantial $18.3B Blackstone-TPG buyout. Company's chief operations officer simultaneously exited equity which paid $76, plus Contingent Value Rights (CVR). There has been a narrative shift surrounding Hologic with an all-cash buyout of $79. Several top officials including the director, president and Senior Vice President had their equity converted to cash in the merger or surrendered their shares. The valuation of Holox is introspected after a three-month share price momentum while assessments continue given recent earnings growth and share price recovery. However, the loss of $277.8M has undermined recovery narratives despite growth forecasts. Hologic Inc. is now closed for public trading following the takeover bid.
Hologic HOLX News Analytics from Thu, 18 Sep 2025 07:00:00 GMT to Thu, 23 Apr 2026 03:05:08 GMT -
Rating 8
- Innovation 4
- Information 7
- Rumor -6
